TXMD vs. CPIX, CDIO, BIOR, NEPH, DMTK, NRSN, MEIP, OCX, EVAX, and PYPD
Should you be buying TherapeuticsMD stock or one of its competitors? The main competitors of TherapeuticsMD include Cumberland Pharmaceuticals (CPIX), Cardio Diagnostics (CDIO), Biora Therapeutics (BIOR), Nephros (NEPH), DermTech (DMTK), NeuroSense Therapeutics (NRSN), MEI Pharma (MEIP), OncoCyte (OCX), Evaxion Biotech A/S (EVAX), and PolyPid (PYPD). These companies are all part of the "medical" sector.
Cumberland Pharmaceuticals (NASDAQ:CPIX) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, community ranking, institutional ownership, media sentiment, analyst recommendations, valuation and risk.
TherapeuticsMD received 199 more outperform votes than Cumberland Pharmaceuticals when rated by MarketBeat users. Likewise, 62.76% of users gave TherapeuticsMD an outperform vote while only 45.28% of users gave Cumberland Pharmaceuticals an outperform vote.
In the previous week, Cumberland Pharmaceuticals had 43 more articles in the media than TherapeuticsMD. MarketBeat recorded 45 mentions for Cumberland Pharmaceuticals and 2 mentions for TherapeuticsMD. Cumberland Pharmaceuticals' average media sentiment score of 0.36 beat TherapeuticsMD's score of -0.18 indicating that TherapeuticsMD is being referred to more favorably in the news media.
Cumberland Pharmaceuticals has a beta of 0.16, meaning that its share price is 84% less volatile than the S&P 500. Comparatively, TherapeuticsMD has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500.
15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 43.3% of Cumberland Pharmaceuticals shares are owned by insiders. Comparatively, 1.2% of TherapeuticsMD shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
TherapeuticsMD has a net margin of 0.00% compared to TherapeuticsMD's net margin of -15.87%. TherapeuticsMD's return on equity of 6.84% beat Cumberland Pharmaceuticals' return on equity.
Cumberland Pharmaceuticals has higher revenue and earnings than TherapeuticsMD.
Summary
TherapeuticsMD beats Cumberland Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
Get TherapeuticsMD News Delivered to You Automatically
Sign up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TXMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TherapeuticsMD Competitors List
Related Companies and Tools
